Alirocumab and Inclisiran: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Inclisiran and PCSK9 antibodies act on the same LDL-lowering target by different mechanisms; this record concerns a planned switch.
Clinical significance and safety
Alirocumab and Inclisiran: A clinician may plan a switch from alirocumab or evolocumab to inclisiran, including timing of the last antibody and first inclisiran doses. This switching information does not recommend routine simultaneous use of two PCSK9-targeted treatments.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.